Shire PLC (SHPG) Earns “Buy” Rating from Shore Capital
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating restated by analysts at Shore Capital in a note issued to investors on Saturday.
SHPG has been the topic of several other reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a research report on Tuesday, June 28th. HSBC cut Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a research report on Monday, October 3rd. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the company a “hold” rating in a research report on Saturday, October 1st. Finally, Leerink Swann restated a “buy” rating and set a $213.00 target price (down from $225.00) on shares of Shire PLC in a research report on Thursday, June 16th. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 194.50 on Friday. The company has a market capitalization of $57.93 billion, a PE ratio of 40.42 and a beta of 1.16. The firm’s 50-day moving average price is $195.56 and its 200 day moving average price is $187.04. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.35. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same period last year, the firm earned $2.63 EPS. Equities analysts predict that Shire PLC will post $12.92 EPS for the current year.
The business also recently declared a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were paid a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quadrant Capital Group LLC raised its position in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares in the last quarter. Canal Insurance CO bought a new position in shares of Shire PLC during the second quarter worth $102,000. FTB Advisors Inc. raised its position in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares in the last quarter. Duncker Streett & Co. Inc. bought a new position in shares of Shire PLC during the second quarter worth $111,000. Finally, Ropes Wealth Advisors LLC bought a new position in shares of Shire PLC during the second quarter worth $114,000. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.